W
WAVEMAN · COMPANY
ELVN · Enliven Therapeutics, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

ELVN

Enliven Therapeutics, Inc.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001672619
FORM 144 · 6☆ WATCH
INSIDER NET · 180D
-$66.1M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
153
13F, latest reported quarter
REVENUE GROWTH
-
XBRL, annual
NET MARGIN
-
CONVERSIONS · 180D
14
codes C/M, not in net · $1.9M priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$66.1M over 180 days
-$63.5M over 90 days · -$51.7M of it by a 10%+ holder
below 96% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
153 funds added or opened last quarter
more than 79% of Pharma & Biotech
REVENUE
no revenue reported in any filing
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
11.1% of shares outstanding short · 11.4 days to cover · settled 2026-07-31
more than 81% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$66.1M across 5 people in 180 days.
153 funds added or opened positions in the latest 13F quarter, of 219 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +184.0%
+184.0%12M
-28%+46%+119%+193%2025-092025-102025-122026-032026-052026-072026-09 2026-06-22 · ORBIMED ADVISORS LLC sold $35.7M2026-06-15 · ORBIMED ADVISORS LLC sold $12.3M2026-08-04 · Derynck Mika K sold $9.6M2026-06-22 · ORBIMED ADVISORS LLC sold $2.1M2026-01-09 · Lyssikatos Joseph P sold $1.5M2026-03-25 · Collins Helen Louise sold $1.4M2026-01-09 · Patel Anish sold $1.3M2026-02-17 · Collins Helen Louise sold $1.2M2026-06-22 · ORBIMED ADVISORS LLC sold $1.1M2026-01-09 · Lyssikatos Joseph P sold $1.0M2026-03-09 · Collins Helen Louise sold $896.7K2026-01-08 · Lyssikatos Joseph P sold $842.3K2026-06-15 · ORBIMED ADVISORS LLC sold $409.1K2026-01-20 · Lyssikatos Joseph P sold $390.3K2026-03-10 · Collins Helen Louise sold $305.8K2026-07-06 · Kunkel Lori Anne sold $299.4K2026-03-06 · Hohl Benjamin sold $295.8K2025-10-20 · Lyssikatos Joseph P sold $276.0K2025-11-17 · Kintz Samuel sold $272.8K2026-08-17 · Hohl Benjamin sold $270.2K2025-11-19 · Lyssikatos Joseph P sold $267.8K2026-06-05 · Kunkel Lori Anne sold $266.7K2025-10-17 · Kintz Samuel sold $266.6K2026-08-17 · Collins Helen Louise sold $227.6K2026-07-06 · Kunkel Lori Anne sold $205.5K2026-01-08 · Heyman Richard A. sold $200.7K2026-01-08 · Lyssikatos Joseph P sold $151.0K2026-06-17 · Hohl Benjamin sold $149.2K2026-02-06 · Lyssikatos Joseph P sold $145.2K2026-01-20 · Lyssikatos Joseph P sold $144.8K2026-07-17 · Hohl Benjamin sold $140.8K2026-03-17 · Collins Helen Louise sold $138.8K2026-05-18 · Collins Helen Louise sold $137.4K2025-09-08 · Patel Anish sold $134.9K2026-07-17 · Hohl Benjamin sold $134.1K2025-10-07 · Patel Anish sold $134.0K2026-04-17 · Collins Helen Louise sold $117.3K2026-07-17 · Collins Helen Louise sold $116.7K2026-04-17 · Collins Helen Louise sold $114.6K2026-06-17 · Collins Helen Louise sold $114.0K2026-07-17 · Collins Helen Louise sold $108.1K2026-01-09 · Heyman Richard A. sold $107.1K2026-09-04 · Heyman Richard A. filed to sell $2.3M2026-08-04 · Derynck Mika K filed to sell $9.2M2026-07-17 · Collins Helen Louise filed to sell $762.9K2026-06-22 · The Biotech Growth Trust PLC filed to sell $1.4M2026-06-22 · OrbiMed Private Investments VII, LP filed to sell $36.2M2026-06-22 · OrbiMed Genesis Master Fund, L.P. filed to sell $1.1M
INSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $66.1M sold by insiders over 180 days, 153 funds added last quarter, $50.9M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Enliven Therapeutics, Inc. insiders sold a net $66.1M of stock across 310 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
Collins Helen Louise
CHIEF MEDICAL OFFICER
SELL
2026-08-17
3,900.0
$227.6K
Collins Helen Louise
CHIEF MEDICAL OFFICER
SELL
2026-08-17
1,100.0
$65.3K
Hohl Benjamin
CHIEF FINANCIAL OFFICER
SELL
2026-08-17
4,630.0
$270.2K
Hohl Benjamin
CHIEF FINANCIAL OFFICER
SELL
2026-08-17
1,388.0
$82.4K
Derynck Mika K
Director
SELL
2026-08-04
158,795.0
$9.6M
310 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 305 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
FMR LLC
10,025,017.0 sh
$508.8M
ORBIMED ADVISORS LLC
6,776,632.0 sh
$343.9M
Polar Capital Holdings Plc
6,430,636.0 sh
$326.4M
BlackRock, Inc.
4,359,704.0 sh
$221.3M
Vestal Point Capital, LP
4,000,000.0 sh
$203.0M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
Heyman Richard A.
FILED 2026-09-04
$2.3M
Derynck Mika K
FILED 2026-08-04
$9.2M
Collins Helen Louise
FILED 2026-07-17
$762.9K
The Biotech Growth Trust PLC
FILED 2026-06-22
$1.4M
OrbiMed Private Investments VII, LP
FILED 2026-06-22
$36.2M
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
$7.5M POSITION · AS OF 2026-03-31
2.4%
PROFUND VP PHARMACEUTICALS
$239.2K POSITION · AS OF 2026-03-31
2.4%
Virtus Biotech Clinical Trials Etf
$674.9K POSITION · AS OF 2026-04-30
1.8%
Direxion Daily Pharmaceutical & Medical Bull 3X Shares
$231.7K POSITION · AS OF 2026-04-30
1.8%
Invesco Dorsey Wright Healthcare Momentum ETF
$1.3M POSITION · AS OF 2026-04-30
1.1%
Lord Abbett Micro-Cap Growth Fund
$1.9M POSITION · AS OF 2026-04-30
0.9%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 4 registered trials, 4 still enrolling or running — a status change here is dated weeks before the press release
4
Phase 1
4 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
OPERATING INCOME$-119.7M$-104.6M$-83.5M$-38.8M
NET INCOME$-103.7M$-89.0M$-71.6M$-37.7M
EPS (DILUTED)-1.83-1.89-2.01-12.05
OPERATING CASH FLOW$-70.3M$-73.2M$-61.3M$-32.1M
CASH$98.9M$124.1M$100.1M$75.5M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →